文献速递临床试验与 GCP基础与转化研究

SP16预防择期心脏手术慢性肾病患者急性肾损伤的IIa期试验方案

Efficacy and safety of SP16 in preventing acute kidney injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2026-08-28

本研究为单中心、随机、双盲、安慰剂对照IIa期试验,计划纳入120例接受体外循环心脏手术的G2-G3b期慢性肾病高危患者,按1:1随机接受SP16 12mg或安慰剂皮下注射。主要终点为术后7天内急性肾损伤发生率和术后72小时内不良事件频率,旨在评估SP16预防心脏手术相关急性肾损伤的疗效与安全性。

要点

  • SP16在临床前显示肾脏和心脏保护作用,I期试验安全。
  • 研究纳入G2-G3b期慢性肾病心脏手术患者120例。
  • 主要终点为术后7天急性肾损伤发生率和72小时不良事件。

核心结论

  • 该IIa期试验将评估SP16预防心脏手术相关急性肾损伤的疗效与安全性。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照IIa期试验,计划纳入120例G2-G3b期慢性肾病患者。
  • 患者按1:1随机接受SP16 12mg或安慰剂,术前和术后9小时各皮下注射一次。

关键数值与推荐

  • 主要终点为术后7天内急性肾损伤发生率和术后72小时内不良事件频率。
  • 次要终点包括第90天主要不良肾脏事件发生率和心脏功能影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac surgery using cardiopulmonary bypass uses controlled hypoperfusion which leads to relative organ damage. Acute kidney injury is the most frequent and most important organ failure, in particular in patients with chronic kidney disease. To date, there are no approved drug treatments that could effectively prevent acute kidney injury. SP16, an agonist of the low-density lipoprotein receptor-related protein 1, has been shown to exert both kidney- and cardioprotective effects in preclinical trials. Early clinical use of SP16 in phase I trials was safe. Administration of SP16 had beneficial trends on inflammatory response and infarct size in patients with ST-segment elevation myocardial infarction. The primary objective of this phase IIa trial is to demonstrate that injection of SP16 is safe and superior to placebo in preventing cardiac surgery-associated acute kidney injury within 7 days after surgery. METHODS: This randomised, double-blinded, placebo-controlled, single-centre study evaluates the efficacy and safety of SP16 in 120 high-risk chronic kidney disease patients with disease stage G2-G3b undergoing cardiac surgery who are randomised into one of two treatment groups in a 1:1 ratio: SP16 (12 mg) or placebo. The study medication is administered via two subcutaneous injections, with the first dose given before surgery, followed by an additional dose after 9 h. Primary endpoints are the incidence of acute kidney injury during 7 days post-surgery and the frequency of adverse events within 72 h after index surgery. Important secondary endpoints include the incidence of major adverse kidney events at day 90 and impact on cardiac function. Safety assessments encompass adverse events, vital signs, electrocardiograms and routine safety laboratory tests. Additional evaluations include pharmacokinetics and immunological biomarkers. DISCUSSION: This single-centre phase IIa trial will assess the incidence of cardiac surgery-associated acute kidney injury, describing the kidney-protective potential of SP16 and its safety profile in patients undergoing cardiac surgery. TRIAL REGISTRATION: EUCT, EUCT number 2025-522491-89-00. Registered on February 2, 2026, https://euclinicaltrials.eu/ctis-public/view/2025-522491-89-00 . Patient recruitment is planned to start on August 1, 2026.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jobst-Schwan T, Bihlmaier K, Austin D, et al. Efficacy and safety of SP16 in preventing acute kidney injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial. Trials. 2026. PMID: 42665834. doi:10.1186/s13063-026-09966-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。